Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 Task Group 43 report on specification for 103Pd and 125I interstitial brachytherapy

Jeffrey F. Williamson, Wayne Butler, Larry A. DeWerd, M. Saiful Huq, Geoffrey S. Ibbott, Zuofeng Li, Michael G. Mitch, Ravinder Nath, Mark J. Rivard, Dorin Todor

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


In March 2004, the recommendations of the American Association of Physicists in Medicine (AAPM) on the interstitial brachytherapy dosimetry using 125I and 103Pd were reported in Medical Physics [TG-43 Update: Rivard et al., 31, 633-674 (2004)]. These recommendations include some minor changes in the dose-calculation formalism and a major update of the dosimetry parameters for eight widely used interstitial brachytherapy sources. A full implementation of these recommendations could result in unintended changes in delivered dose without corresponding revisions in the prescribed dose. Because most published clinical experience with permanent brachytherapy is based upon two widely used source models, the 125I Model 6711 and 103Pd Model 200 sources, in this report we present an analysis of the dosimetric impact of the 2004 TG-43 dosimetry parameters on the history of dose delivery for these two source models. Our analysis indicates that the currently recommended prescribed dose of 125 Gy for Model 200 103Pd implants planned using previously recommended dosimetry parameters [AAPM 103Pd dose prescription: Williamson et ai, Med. Phys. 27, 634-642 (200O)] results in a delivered dose of 120 Gy according to dose calculations based on the 2004 TG-43 update. Further, delivered doses prior to October 1997 varied from 113 to 119 Gy for a prescribed dose of 115 Gy compared to 124 Gy estimated by the AAPM 2000 report. For 125I implants using Model 6711 seeds, there are no significant changes (less than 2%). Practicing physicians should take these results into account when selecting the clinically appropriate prescribed dose for 103Pd interstitial implant patients following implementation of the 2004 TG-43 update dose-calculation recommendations. The AAPM recommends, that the radiation oncology community review this report and consider whether the currently recommended dose level (125 Gy) needs to be revised.

Original languageEnglish
Pages (from-to)1424-1439
Number of pages16
JournalMedical physics
Issue number5
StatePublished - May 2005


  • Air-kerma strength
  • Dose prescriptions
  • I
  • Pd
  • Permanent interstitial brachytherapy


Dive into the research topics of 'Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 Task Group 43 report on specification for <sup>103</sup>Pd and <sup>125</sup>I interstitial brachytherapy'. Together they form a unique fingerprint.

Cite this